Unlike psychopharmacologic interventions for other psychiatric conditions, few medications have emerged as helpful in improving eating disorder cognitions and evidence-based psychotherapies fail many patients. Novel treatments are urgently needed to address anorexia nervosa (AN), which is increasingly prevalent and difficult to treat. This article provides an overview of preliminary investigations into cannabidiol, psilocybin therapy, ketamine and the ketogenic diet, transcranial magnetic stimulation, and vagus nerve stimulation in individuals with AN. These pilot studies underscore the need for larger clinical trials that include more participant diversity in order to rapidly translate findings to real-world clinical practice.
Keyphrases
- anorexia nervosa
- transcranial magnetic stimulation
- clinical trial
- clinical practice
- high frequency
- end stage renal disease
- physical activity
- ejection fraction
- newly diagnosed
- mental health
- prognostic factors
- peritoneal dialysis
- stem cells
- study protocol
- mesenchymal stem cells
- case control
- replacement therapy
- patient reported